Denali Therapeutics Inc. DNLI Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s common stock, shares authorized (in shares)?
- Denali Therapeutics Inc. (DNLI) reported common stock, shares authorized (in shares) of $400M in Q1 2026.
- How has Denali Therapeutics Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Denali Therapeutics Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $400M to $400M.
- What is the long-term trend for Denali Therapeutics Inc.'s common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $400M to $400M.